Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb–mediated tumor lysis. Herein, we report phase I r...

Descripción completa

Detalles Bibliográficos
Autores principales: Paz-Ares, Luis, Champiat, Stephane, Lai, W. Victoria, Izumi, Hiroki, Govindan, Ramaswamy, Boyer, Michael, Hummel, Horst-Dieter, Borghaei, Hossein, Johnson, Melissa L., Steeghs, Neeltje, Blackhall, Fiona, Dowlati, Afshin, Reguart, Noemi, Yoshida, Tatsuya, He, Kai, Gadgeel, Shirish M., Felip, Enriqueta, Zhang, Yiran, Pati, Amrita, Minocha, Mukul, Mukherjee, Sujoy, Goldrick, Amanda, Nagorsen, Dirk, Hashemi Sadraei, Nooshin, Owonikoko, Taofeek K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414718/
https://www.ncbi.nlm.nih.gov/pubmed/36689692
http://dx.doi.org/10.1200/JCO.22.02823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414718/
https://www.ncbi.nlm.nih.gov/pubmed/36689692
http://dx.doi.org/10.1200/JCO.22.02823

Ejemplares similares